Maze Therapeutics MAZE
NASDAQ MAZE
$35.06 +0.15 (+0.43%)
As of: Nov 10, 2026 · 2:18 PM EST

Maze Therapeutics (MAZE) Total Debt (2026)

Updated

Maze Therapeutics' Total Debt was $38.96 million in Q2 2026, up 0.3% from the prior quarter.

Analysis

Maze Therapeutics (MAZE) Total Debt (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 49.50 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 44.65 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 80.90 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 53.78 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 9.59 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 32.35 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 54.01 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 26.23 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 62.67 Bn
10 Maze Therapeutics 2.05 Bn 561.97 Mn - 38.96 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 38.96 Mn
Mar 31, 2026 38.83 Mn
API Access

Maze Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=MAZE&period=max&api_key=YOUR_API_KEY